Last Updated: 09 Nov 2024
Executive Summary
Edwards Lifesciences Corp (EW) is a leading medical technology company specializing in artificial heart valves and hemodynamic monitoring. With a strong financial performance, the company has a healthy market capitalization of $39.06 billion and a trailing price-to-earnings ratio of 25.57. Analysts are generally bullish on EW, with a consensus rating of "Buy" and an average target price of $75.12.
Company Overview
Edwards Lifesciences is headquartered in Irvine, California. The company's products are used in a variety of cardiovascular procedures, including heart valve replacement, repair, and transcatheter aortic valve replacement (TAVR). Edwards Lifesciences has a global presence, with operations in over 100 countries.
Fundamental Analysis
EW's financial performance has been strong in recent years. The company's revenue has grown at a steady pace, reaching $6.31 billion in the trailing twelve months. Net income has also increased, reaching $2.05 billion in the same period. Edwards Lifesciences has a healthy profit margin of 65.9% and an operating margin of 29.1%. The company's return on assets and return on equity are also strong, at 10.6% and 19.1%, respectively.
Technical Analysis
EW's stock price has been trending lower in recent months. The stock is currently trading at $66.23, below its 50-day moving average of $67.67 and its 200-day moving average of $80.31. The relative strength index (RSI) is currently at 36.5, indicating that the stock is oversold.
Short Term Outlook
In the short term, EW's stock price is likely to continue to trade lower. The stock is currently below its key moving averages and the RSI is oversold. However, the company's strong fundamentals could provide support for the stock price.
Long Term Outlook
In the long term, EW's stock price is likely to perform well. The company has a strong track record of financial performance and is a leader in the medical technology industry. The aging population and the increasing prevalence of cardiovascular disease should drive demand for Edwards Lifesciences' products in the years to come.
Analyst Recommendations
Analysts are generally bullish on EW. The consensus rating is "Buy" and the average target price is $75.12. Three analysts have a "Strong Buy" rating on the stock, 11 have a "Buy" rating, 17 have a "Hold" rating, and 1 has a "Strong Sell" rating.
